-Down to Earth India’s GDP for health is less than 1.5 per cent and is one of the lowest in the world Health infrastructure, especially in the rural areas, is going to be one of the challenging tasks ahead for the new government. In its last tenure, it brought the Ayushman Bharat scheme — the government run health insurance programme — which was seen as a major health policy intervention. However, according...

-CaravanMagazine.in India is often hailed for its democracy, for empowering its poor and ordinary citizens to participate in the electoral process and play a role in shaping the country. This narrative has increasingly come under strain since the Supreme Court, through its March 2003 judgment in Union of India vs Association for Democratic Reforms, made it mandatory for candidates contesting elections to disclose their wealth, educational qualification, and criminal cases pending...

-The Indian Express Amid the ongoing controversy that erupted with PepsiCo India’s lawsuits against 11 farmers for growing its patented potato variety, The Indian Express meets the affected farmers to find the genesis of the problem . Among the 11 farmers of Gujarat who have been slapped lawsuits by PepsiCo India for “illegally” growing its patented potato variety FL 2027, are Fulchand Kachchhawa and his brother Suresh of Malgadh village in...

-The Hindu Business Line PepsiCo’s case against Gujarat’s potato growers was a patently weak one Right at the outset, it was apparent that PepsiCo never had a strong legal case against farmers growing its registered potato variety without entering into a contract. After pressure from farmers’ groups, PepsiCo has decided to withdraw cases against about 10 farmers in Gujarat and Rajasthan who were allegedly cultivating its FC-5 variety — registered by it...

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...